DBV Technologies S.A. (DBVT)
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.
Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.
The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis.
Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes.
The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers.
DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
177-181 avenue Pierre Brossolette
Montrouge, Ile De France 92120
|Phone||33 1 55 42 78 78|
|Fiscal Year||January - December|
|Daniel Tassé||Chief Executive Officer and Director|
|Sébastien Robitaille||Chief Financial Officer|
|Dr. Pharis Mohideen||Chief Medical Officer|
|Pascal Wotling||Chief Technical Operations Officer and Chief Quality Officer|
|Anne Pollak||Head of Investor Relations|
|Michele F. Robertson||Chief Legal Officer|
|Joseph Becker||Vice President of Global Corporate Communications|
|Caroline Daniere||Chief Human Resources Officer and Chief of Staff|
|Dr. Wence Agbotounou||Chief Clinical Trial Officer and Senior Vice President|
|Lucie Mondoulet||Senior Vice President and Deputy CSO|
Latest SEC Filings
|Jun 16, 2022||SC 13D/A||General statement of acquisition of beneficial ownership|
|Jun 13, 2022||4||Statement of changes in beneficial ownership of securities|
|Jun 13, 2022||SC 13D/A||General statement of acquisition of beneficial ownership|
|Jun 13, 2022||8-K||Current report|
|Jun 7, 2022||8-K||Current report|
|May 25, 2022||F-6EF||Registration of American Depository Receipt shares, immediately effective|
|May 16, 2022||8-K||Current report|
|May 2, 2022||8-K||Current report|
|May 2, 2022||424B5||Prospectus [Rule 424(b)(5)]|
|May 2, 2022||10-Q||Quarterly report [Sections 13 or 15(d)]|